Table 1.
Overview of characteristics of prospective trials on oligometastatic disease in NSCLC.
| Author | Iyengar 2017 [12] |
Gomez 2016 & 2019 [10,11] |
De Ruysscher 2012 & 2018 [13,14] |
Arrieta 2019 [15] |
Petty 2018 [16] |
Collen 2014 [17] |
Bauml 2019 [27] |
|---|---|---|---|---|---|---|---|
| Trial type | Single center phase II RCT | Multicenter phase II RCT | Single arm phase II | Single armphase II | Multicenter Single arm phase II | Single arm phase II | Single arm phase II |
| Patients n | 29 | 49 | 39 | 37 | 29 | 26 | 45 |
| Period of inclusion | 2014–2016 | 2012–2016 | 2006–2010 | 2015–2017 | 2010–2015 | NR | 2015–2017 |
| Eligibility assessment | After CT | After CT/TKI | Before any treatment | Before any treatment | Before or after CT | Before LAT | After LAT |
| Synchronous | 100% | 94% | 100% | 100% | 0% | 73% | 31% |
| Metachronous | 0% | 6% | 0% | 0% | 100% | 27% | 69% |
| Max n of M+ | 5 | 3 | 5 | 5 | 5 | 5 | 4 |
|
Histology
nonsquamous squamous |
93% 7% |
90% 10% |
79% 21% |
95% 5% |
78% 22% |
92% 8% |
82% 18% |
| Mean/median age (years) | NR/64 | 63/61 | 62/NR | 56/NR | NR/65 | 62/NR | NR/64 |
| Single metastasis | NR | 65% | 87% | 38% | 11% | 54% | 62% |
| cN2/N3 | NR | 53% | 74% | NR | 40% | 52% | 36% |
| Driver mutations | 0% | 16% | NR | 43% | NR | NR | NR |
| Systemic R/ | CT +/− maint |
CT/TKI +/− maint |
CT/TKI/no | CT/TKI +/− maint (70%) |
CT | CT/TKI/no | ICI |
| Response needed for LAT | At least SD | At least SD | No requirement | At least SD | At least SD | No requirement | - |
| LAT | SABR | RT/S | RT/S | RT/S/RFA | RT | SABR | RT/S/RFA |
| RT dose | 21–27 Gy/1 # 27–33 Gy/3 # 30–38 Gy/5 # (45 Gy/15 #) |
NR | EQD2 ≥ 60 Gy | NR | 24–27 Gy/1 # 54 Gy/3 # 50 Gy/5 # 60 Gy/30 # |
50 Gy/10 # | NR |
| FDG-PET-CT | Not mandatory | Not mandatory | At diagnosis | At diagnosis, before inclusion & Follow-up |
Not mandatory | Diagnosis & Follow-up |
NR |
| Median FUP (m) (range) | 10 (2–30) |
39 (28–61) |
Minimum of 84 | 33 | 24 | 16 (33–40) |
25 |
|
Median PFS w LAT (m)
(95% CI) |
10 | 14 (7–23) |
12 (10–14) |
24 (14–33) |
11 (8–16) |
11.2 | 19 (9–29) |
| Median PFS w/o LAT (m) (95% CI) | 4 |
4 (2–8) |
- | - | - | - | - |
|
Median OS (m)
(95% CI) |
Not reached | 41 (19 to not reached) |
14 (8–19) |
Not reached | 28 (15–46) |
23 | 41 (27–56) |
| Median OS w/o LAT (m) (95% CI) | 17 NR |
17 (10–40) |
- | - | - | - | - |
| 2y PFS | NR | 14% | 46% * | 22% * | NR | NR | |
| 2y OS | NR | 67% * | 23% | 75% * | 52% * | NR | 78% |
| Toxicity w LAT | 4 G3 | 5 G3 | 3 G3 | 8 G3 1 G4 |
0 G3 |
2 G3 | 5 G3 1 G4 |
| Toxicity w/o LAT | 2 G3 1 G4 |
2 G3 | - | - | - | - | - |
* derived from graphs in publication; #: number of fractions; CT: chemotherapy; CI: confidence interval; ICI: immune checkpoint inhibitor; maint: maintenance systemic therapy; NR: not reported; RCT: randomized controlled trial; RT: radiotherapy; SABR: stereotactic ablative RT; S: surgery: RFA: radiofrequency ablation; NR: not reported; LAT: local ablative therapy; G: Grade; m: months; w: with; w/o: without; and EQD2: equivalent dose in 2Gy fractions.